Objectives: An increasing prevalence since 2010 of Serratia marcescens harbouring the Ambler class A carbapenemase SME prompted us to further characterize these isolates.
Introduction
A clavulanate-inhibited carbapenemase was characterized in 1990 from Serratia marcescens S6, 1 initially isolated in 1982, and its gene, bla SME-1 , was sequenced in 1994. 2 Since then two additional variants, SME-2 and SME-3 (single amino acid variants of SME-1), have been characterized. 3, 4 Single isolates or small groups of S. marcescens harbouring SME-type enzymes have been reported in the USA, Canada, Argentina and Switzerland. 3,5 -10 Here we describe the increasing occurrence of S. marcescens isolates harbouring bla SME from across Canada and characterize a novel genomic island that harbours bla SME .
Materials and methods

Bacterial isolates
S. marcescens isolates were voluntarily submitted to the National Microbiology Laboratory (NML) between 1 January 2010 and 31
December 2012 for detection of carbapenemase genes. Patient data, including travel history and classification as community or hospital acquired, were also obtained when available.
PCR and DNA methodology
Primers used in this study are listed in Table S1 (available as Supplementary data at JAC Online). Multiplex PCR for carbapenemases, b-lactamases and bla SME was as previously described. 11 Macrorestriction/ PFGE using XbaI was analysed with BioNumerics v5.1 (Applied Maths, Saint Martens-Latem, Belgium).
Whole-genome sequencing and bioinformatics
Genome sequencing was conducted using Illumina technology (GAIIe; Illumina, San Diego, CA, USA) with de novo assembly done with Edena v0.0.4. We used progressiveMAUVE 12 to order the contigs to the S. marcescens WW4 genome (accession number CP003959). Annotation was done manually using the BLAST suite (http://blast.ncbi.nlm.nih.gov/Blast.cgi) and by comparison with the annotated genomes of S. marcescens WW4 or FGI94 (accession number CP993942). Antimicrobial susceptibility and phenotypic testing Antimicrobial susceptibilities were determined using Vitek 2 and Etest and interpreted based on CLSI 2012 guidelines 13 or, for tigecycline, FDA breakpoint criteria for Enterobacteriaceae. The modified Hodge test was done following CLSI guidelines. 13 The Carba NP test 14 was carried out with modifications as previously described. 15 Briefly, a 10 mL loopful of bacteria was vortexed for 10 s in lysis buffer and then mixed with phenol red solution with or without 6 mg/L imipenem and the tubes were monitored for a colour change for up to 120 min.
Nucleotide accession numbers
The sequences of the SmarGI1-1 and flanking regions from S. marcescens N10-0408, N11-2820 and N12-0620 have been assigned accession numbers KF445086, KF318367 and KF615855, respectively, in the GenBank database.
Results and discussion
S. marcescens isolates and patient information
A total of 75 S. marcescens, 13 in 2010, 33 in 2011 and 29 in 2012, were submitted to the NML for carbapenemase gene testing. Thirty (40%) of the isolates harboured a bla SME gene (24 bla SME-1 and 6 bla SME-2 ), 4 from 2010 (31%), 8 from 2011 (24%) and 18 from 2012 (62%). Of the remaining 45 isolates, 8 harboured bla KPC , 1 harboured bla GES-5 and 36 were negative for all genes tested. Among isolates harbouring bla SME , 50% and 33% were obtained from British Columbia and Quebec, respectively, though there were no known outbreaks associated with these isolates. Patients' ages ranged from 42 to .65 years; 60% of patients were .65 years of age and 60% were male. Sites of isolation included the lower respiratory tract (n¼ 13), urine (n¼8), wounds (n¼ 4), blood (n¼ 1) and other (n ¼4). Two patients reported travel to the USA within the previous year and 10 patients reported no travel. Acquisition was classified as community acquired for three isolates and hospital acquired for one isolate.
Phenotypic detection
The modified Hodge test was not reliable for detection of the SME enzyme as 30% of isolates (9/30) were not positive ( Figure 1 ). In our hands the Carba NP test 14 was also suboptimal for SME detection as 27% (8/30) of isolates gave a negative result ( Figure 1 ). However, all eight false negative isolates were positive using a modified Carba NP test, 15 indicating increased sensitivity of this test format ( Figure 1 ).
Antimicrobial susceptibility
Susceptibility to b-lactams was typical of S. marcescens harbouring SME enzymes, with a profile of resistance to carbapenems and penicillins but susceptibility to third-generation cephalosporins (Table S2 , available as Supplementary data at JAC Online). All isolates were susceptible to fluoroquinolones and trimethoprim/sulfamethoxazole, all but one to aminoglycosides and all but one to piperacillin/ tazobactam. Two isolates were intermediate to tigecycline.
Macrorestriction analysis
Macrorestriction analysis revealed that 57% of the isolates fell into one of three clusters (more than three isolates), each containing multiple fingerprints with .85% similarity ( Figure 1 ). Cluster I contained eight isolates harbouring bla SME-1 and cluster II contained five isolates harbouring bla SME-2 , with isolates in both clusters isolated in all 3 years. Cluster III contained four bla SME-1 -harbouring isolates, all isolated in 2012. Thus, three widely disseminated pulsotype clusters were predominant in Canada, though, as stated above, none was associated with known outbreaks. All three clusters shared 77% similarity, indicating that there may be at least some clonality in SME-harbouring isolates.
Genetic context of bla SME
The bla SME gene has previously been demonstrated to be chromomosomal. 2, 10 In order to determine the genetic context of bla SME we carried out whole-genome sequencing on three isolates, N12-00620 (cluster I), N10-00408 (cluster II) and N11-02820, a sporadic isolate, and characterized the bla SME regions. A complete listing of the reading frames and their putative products for the bla SME regions is found in Table S3 (available as Supplementary data at JAC Online). For all three isolates the bla SME gene was found in a novel 28.4 kb region that began 400 bp downstream of the smpB gene (SMWW4_v1c37920) (Figure 2a ). The SmpB protein binds to the tmRNA encoded by the ssrA gene located just downstream (not annotated in the S. marcescens WW4 genome) and the SmpB-tmRNA complex is the major component of a ribosome rescue system in bacteria. 16 The Enterobacteriaceae ssrA 3 ′ -end is well known as an integration site (attB) for integrative genetic elements. 17 Thus, not surprisingly, the first gene identified downstream of smpB-ssrA was a gene, intA1, encoding an integrase of the P4 subfamily (Figure 2a ). With the 3 ′ -end of ssrA defining one end of an integrative element, attL, the other end, attR, was identified by analysing an alignment of the novel regions from the three bla SME -harbouring isolates (Figure 2a) . Thus, in all three isolates these 25 bp imperfect direct repeats flank an 28.4 kb genomic island we named SmarGI1-1 (S. marcescens genomic island 1-1). Within SmarGI1-1 we identified 30 genes, either complete or truncated (Figure 2a and Table S3 , available as Supplementary data at JAC Online). Notably, the left 12.4 kb contains a number of genes encoding proteins indicative of the remnants of a prophage while the remaining 16 kb consists of the bla SME -smeR region, and includes three presumably defective IS3 family insertion sequences (IS-d1, -d2, -d3), one of which is interrupted by an IS110 family, ISSm3. The region downstream of the attR site up to a membrane protein gene found in all three isolates is identical in S. marcescens N10-00408 and N12-00620 (2.8 kb), but is larger (11.3 kb) and of completely different sequence in S. marcescens N11-02820 (Figure 2a) . The membrane protein gene and the downstream region are highly similar for all three isolates except for a LysR family regulator gene that is missing in S. marcescens N11-02820 (Figure 2a) . We also note that, besides the macro-differences described above, there were other smaller sequence differences, including single-nucleotide variations (SNVs) and small indels between the analysed regions within both SmarGI1-1 and the flanking regions (data not shown).
Detection of SmarGI1-1 in other isolates
PCR for the left junction of SmarGI1-1 was positive in all other isolates, whereas the right junction as found for S. marcescens
Mataseje et al. (Figure 1) . PCR for the right junction region as found in N11-02820 (R2) was negative for the other three isolates, though the right extremity of SmarGI1-1 was present (PCR 6, Figure 2a) , indicating variation downstream of attR. Further, the 3.9 kb region downstream of bla SME and the 4.6 kb region downstream of smeR were present in all isolates (PCRs 1 -5, Figure 2a) .
N10-00408 (R1) was detected in 26 isolates
Excision, circularization of SmarGI1-1 and chromosome rejoining
The presence of the direct repeats attL and attR suggests a mechanism of integration via site-specific recombination involving a circular intermediate of SmarGI1-1. Using nested PCR, a circular intermediate of SmarGI1-1 was detected in all 30 isolates. For S. marcescens N10-00408 and N11-02820, sequence analysis showed the SmarGI1-1 join site attP was identical to attR and also that the attB site was reconstituted in the chromosome (Figure 2b ). Transfer to E. coli of bla SME by conjugation or by mobilization by an IncP1 plasmid with a broad host range were reported to be unsuccessful.
1 Though self-transfer appears not to occur, our findings of SmarGI1-1 in multiple genetically unrelated S. marcescens isolates suggests transfer to other isolates may occur if necessary functions are supplied in trans. Transfer of a genomic island by mobilization by IncA/C plasmids has recently been demonstrated for the Salmonella genomic island-1 (SGI-1) of Salmonella enterica serovars. 
Conclusions
The NML has received an increasing number of S. marcescens potentially resistant to carbapenems since 2010, with 40% harbouring a bla SME gene. This may be an underrepresentation as all samples received were voluntarily submitted and do not represent national surveillance data. Despite susceptibility to carbapenems in some cases, S. marcescens harbouring bla SME can be reliably detected by a modified Carba NP test. A genomic island, SmarGI1-1, carries the bla SME gene and can exist in a circular form, which may contribute to its transfer amongst different S. marcescens isolates. Though S. marcescens harbouring bla SME have been found almost exclusively in North and South America, their increasing occurrence is a worrisome trend. Identification of these particular isolates in a healthcare setting ensures that there is a reduced chance of transfer of the carbapenemase due to its chromosomal location, especially with concurrent infection control protocols to prevent clonal spread of these organisms. 19 
